Objective: To map the occurrence of amyloid types in a large clinical cohort using mass spectrometry-based shotgun proteomics, an unbiased method that unambiguously identifies all amyloid types in a single assay. Methods: A mass spectrometry-based shotgun proteomics assay was implemented in a central reference laboratory. We documented our experience of typing 16,175 amyloidosis specimens over an 11year period from January 1, 2008, to December 31, 2018. Results: We identified 21 established amyloid types, including AL (n¼9542; 59.0%), ATTR (n¼4600; 28.4%), ALECT2 (n¼511; 3.2%), AA (n¼463; 2.9%), AH (n¼367; 2.3%), AIns (n¼182; 1.2%), KRT5-14 (n¼94; <1%), AFib (n¼71; <1%), AApoAIV (n¼57; <1%), AApoA1 (n¼56; <1%), AANF (n¼47; <1%), Ab2M (n¼38; <1%), ASem1 (n¼34; <1%), AGel (n¼29; <1%), TGFB1 (n¼29; <1%), ALys (n¼15; <1%), AIAPP (n¼13; <1%), AApoCII (n¼11; <1%), APro (n¼8; <1%), AEnf (n¼6; <1%), and ACal (n¼2; <1%). We developed the first comprehensive organ-by-type map showing the relative frequency of 21 amyloid types in 31 different organs, and the first type-by-organ map showing organ tropism of 18 rare types. Using a modified bioinformatics pipeline, we detected amino acid substitutions in cases of hereditary amyloidosis with 100% specificity. Conclusion: Amyloid typing by proteomics, which effectively recognizes all amyloid types in a single assay, optimally supports the diagnosis and treatment of amyloidosis patients in routine clinical practice.